LILRB4/ILT3/CD85k rHuz mAb (Ref: Merck patent)
Application
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Reactivity
Human
Target
| Target Name | LILRB4 / ILT3 / CD85k |
| Target Uniprot | Q8NHJ6 |
Overview
| Catalog# | BIO0050SM |
| Product Name | Anti-human LILRB4 / ILT3 / CD85k (Merck patent Anti-ILT3 complex Biosimilar) |
Specifications
| Conjugation | None |
| Formulation | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| Storage | For long term storage, the produce should be stored at -20℃ or lower. |
| Reconstitution | Dissolve with sterile ddH2O |
| Concentration | Lot Dependent |
| Isotype | Human IgG |
| Calculated M.W. | 144.36 kDa |
| Endotoxin | <0.001 EU/ug |
| Expression System | CHO |
| Purification | Protein A |
Frequently asked questions
Which applications is LILRB4/ILT3/CD85k rHuz mAb (Ref: Merck patent) (BIO0050SM) validated for, and at what dilution?
BIO0050SM is validated for In Vivo Research.